Health
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger – Business Wire
Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial fibrillation (AFib) or atrial flutter. Breakthrough Designation entitles the platform to an expedited regulatory process.
…
-
Noosa News10 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News9 hours agoLyka Doggie Date Night at Moonlight Cinema
-
Noosa News8 hours agoQueensland Drug and Alcohol Court provides sentencing options – Proctor
-
Business10 hours agoSolid superannuation gains continue to roll in